Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma

被引:0
|
作者
Shuai Xu [1 ,2 ]
Xiu-Ping Zhang [1 ]
Guo-Dong Zhao [1 ]
Wen-Bo Zou [1 ]
Zhi-Ming Zhao [1 ]
Qu Liu [1 ]
Ming-Gen Hu [1 ]
Rong Liu [1 ]
机构
[1] Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center, Chinese PLA General Hospital
[2] Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University
关键词
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
摘要
Background: The prognosis of patients with pancreatic ductal adenocarcinoma(PDAC) remains poor even after radical pancreaticoduodenectomy(PD). The study aimed to develop and validate a novel preoperative prognostic model to accurately predict the long-term survival of patients with PDAC.Methods: Patients with PDAC of pancreatic head from Chinese PLA General Hospital were included. The preoperative PDAC model with contour plots was developed using a non-linear model in the training cohort and then tested in the validation cohort.Results: Of 421 patients who met the inclusion criteria, 280 were in the training cohort and 141 in the validation cohort. Contour plots for preoperative PDAC model were established to visually predict the survival probabilities of these patients, based on preoperative carbohydrate antigen 19-9, preoperative fibrinogen to albumin ratio and pain symptoms. This model stratified patients into low-and high-risk groups with distinctly different long-term survival in the training cohort [median overall survival(OS)32.1 vs. 17.5 months; median recurrence-free survival(RFS) 19.3 vs. 10.0 months, both P < 0.001] and the validation cohort(median OS 28.3 vs. 19.0 months; median RFS 17.5 vs. 11.2 months, both P < 0.001).Time-dependent receiver operating characteristic and decision curve analyses revealed that the model provided higher diagnostic accuracy and superior net benefit compared to other staging systems.Conclusions: This study constructed and validated a novel preoperative prognostic model that can accurately and conveniently predict the long-term survival of patients with resectable PDAC of pancreatic head. Besides, the model can screen high-risk patients with poor prognosis, which may provide references for personal treatment strategies in the future.
引用
收藏
页码:160 / 168
页数:9
相关论文
共 50 条
  • [31] Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
    Gruber, Elisabeth S.
    Jomrich, Gerd
    Tamandl, Dietmar
    Gnant, Michael
    Schindl, Martin
    Sahora, Klaus
    PLOS ONE, 2019, 14 (05):
  • [32] Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma
    Liu Wen-Jing
    Zhou Li
    Liang Zhi-Yong
    Zhou Wei-Xun
    You Lei
    Zhang Tai-Ping
    Zhao Yu-Pei
    中华医学杂志英文版, 2018, 131 (24) : 2947 - 2952
  • [33] Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma
    Dong, Qian
    Zhang, Yao
    Yang, Xiang-hong
    Jing, Wei
    Zheng, Li-qiang
    Liu, Yun-peng
    Qu, Xiu-juan
    Li, Zhi
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (05) : 639 - 648
  • [34] Serum aspartate aminotransferase is an adverse prognostic indicator for patients with resectable pancreatic ductal adenocarcinoma
    He, Meifang
    Liu, Yin
    Huang, Hefei
    Wu, Jiali
    Wu, Juehui
    Wang, Ruizhi
    Wang, Dong
    LABORATORY MEDICINE, 2023, 54 (06) : 608 - 612
  • [35] Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma
    Liu, Wen-Jing
    Zhou, Li
    Liang, Zhi-Yong
    Zhou, Wei-Xun
    You, Lei
    Zhang, Tai-Ping
    Zhao, Yu-Pei
    CHINESE MEDICAL JOURNAL, 2018, 131 (24) : 2947 - +
  • [36] Development and validation of a radiomics model of magnetic resonance for predicting liver metastasis in resectable pancreatic ductal adenocarcinoma patients
    Yuzhou Huang
    Shurui Zhou
    Yanji Luo
    Jinmao Zou
    Yaqing Li
    Shaojie Chen
    Ming Gao
    Kaihong Huang
    Guoda Lian
    Radiation Oncology, 18
  • [37] Development and validation of a radiomics model of magnetic resonance for predicting liver metastasis in resectable pancreatic ductal adenocarcinoma patients
    Huang, Yuzhou
    Zhou, Shurui
    Luo, Yanji
    Zou, Jinmao
    Li, Yaqing
    Chen, Shaojie
    Gao, Ming
    Huang, Kaihong
    Lian, Guoda
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [38] Identification and Validation of Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Necroptosis-Related Genes
    Xie, Haoran
    Xu, Jingxian
    Xie, Zhiwen
    Xie, Ni
    Lu, Jiawei
    Yu, Lanting
    Li, Baiwen
    Cheng, Li
    FRONTIERS IN GENETICS, 2022, 13
  • [39] DERIVATION OF A BIOBANK OF PANCREATIC DUCTAL ADENOCARCINOMA XENOGRAFTS
    Morandi, E.
    Monteleone, M.
    Merlini, D. A.
    Vignati, G.
    D'Aponte, T.
    Castoldi, M.
    Bani, M. R.
    Giavazzi, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E3 - E3
  • [40] Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma Preoperative Planning, Technical Considerations, and Building a Program
    Drake, Justin
    Anaya, Daniel A.
    Fleming, Jason B.
    Denbo, Jason W.
    SURGICAL CLINICS OF NORTH AMERICA, 2024, 104 (05) : 1031 - 1048